- Home
- IGC vs GRCE Comparison
IGC vs GRCE Comparison
Compare IGC & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- GRCE
- Stock Information
- Founded
- IGC 2005
- GRCE 2002
- Country
- IGC United States
- GRCE United States
- Employees
- IGC N/A
- GRCE N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- GRCE
- Sector
- IGC Health Care
- GRCE
- Exchange
- IGC Nasdaq
- GRCE NYSE
- Market Cap
- IGC 29.4M
- GRCE 30.9M
- IPO Year
- IGC N/A
- GRCE N/A
- Fundamental
- Price
- IGC $0.33
- GRCE $3.48
- Analyst Decision
- IGC Strong Buy
- GRCE
- Analyst Count
- IGC 2
- GRCE 0
- Target Price
- IGC $3.75
- GRCE N/A
- AVG Volume (30 Days)
- IGC 380.9K
- GRCE 80.7K
- Earning Date
- IGC 02-12-2025
- GRCE 02-07-2025
- Dividend Yield
- IGC N/A
- GRCE N/A
- EPS Growth
- IGC N/A
- GRCE N/A
- EPS
- IGC N/A
- GRCE N/A
- Revenue
- IGC $1,183,000.00
- GRCE N/A
- Revenue This Year
- IGC N/A
- GRCE N/A
- Revenue Next Year
- IGC $13.38
- GRCE N/A
- P/E Ratio
- IGC N/A
- GRCE N/A
- Revenue Growth
- IGC N/A
- GRCE N/A
- 52 Week Low
- IGC $0.27
- GRCE $2.13
- 52 Week High
- IGC $0.91
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- IGC 41.18
- GRCE N/A
- Support Level
- IGC $0.31
- GRCE N/A
- Resistance Level
- IGC $0.37
- GRCE N/A
- Average True Range (ATR)
- IGC 0.02
- GRCE 0.00
- MACD
- IGC -0.00
- GRCE 0.00
- Stochastic Oscillator
- IGC 28.17
- GRCE 0.00
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.